Answers are grounded in this paper and cite their sources.
Positron emission tomography imaging of serotonin transporter (SERT) is useful for studying brain diseases with altered serotonergic function. A deuterated imaging agent, ([ 18 F]2‐((2‐((bis(methyl‐ d 3 )amino)methyl)‐4‐(3‐fluoropropoxy‐1,1,2,2,3,3‐ d 6 )phenyl)thio)aniline, [ 18 F]D12FPBM, [ 18 F] 1 ), was prepared as a new chemical entity. The deuterated agent, 1 , showed excellent binding affinity to SERT; Ki was 0.086 nM, comparable with the undeuterated FPBM. In vivo biodistribution studies in rats with [ 18 F] 1 showed good brain uptake (1.09% dose/g at 2 min post injection) and high specific uptake into the hypothalamus (HY) as compared with cerebellum (CB) (HY/CB = 7.55 at 120 min), suggesting a specific localization to SERT binding sites. Regional brain distribution in rats provided clear indication that [ 18 F] 1 concentrated in the hypothalamus, hippocampus, and striatum, areas with a high SERT density. Results indicate that very little D to H substitution effect was found; [ 18 F]FPBM and [ 18 F] 1 showed very similar SERT binding. [ 18 F] 1 might be an excellent candidate for SERT imaging.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: